(Q34763641)

English

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Myriam Locatelli-Sanchez

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sébastien Couraud

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dominique Arpin

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Robert Riou

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Pierre-Paul Bringuier

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Pierre-Jean Souquet

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

9 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

191

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

491-499

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

A simple view on lung cancer biology: The EGFR pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Screening for EGFR mutations in lung cancer, a report from India.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

[What is the best sequence of treatment for patients with EGFR mutations?].

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Tumour molecular profiling for deciding therapy-the French initiative.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status f

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1007%2FS00408-013-9482-4

21 January 2018

A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23749122

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00408-013-9482-4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34763641&oldid=2197018095"